Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Consolidated Net Income: 2013-2024

Historic Consolidated Net Income for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$105.5 million.

  • Zevra Therapeutics' Consolidated Net Income rose 98.36% to -$544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 139.40%. This contributed to the annual value of -$105.5 million for FY2024, which is 129.13% down from last year.
  • Zevra Therapeutics' Consolidated Net Income amounted to -$105.5 million in FY2024, which was down 129.13% from -$46.0 million recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' Consolidated Net Income peaked at -$8.6 million during FY2021, and registered a low of -$105.5 million during FY2024.
  • Over the past 3 years, Zevra Therapeutics' median Consolidated Net Income value was -$46.0 million (recorded in 2023), while the average stood at -$59.4 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Consolidated Net Income surged by 47.94% in 2020, and later slumped by 212.94% in 2022.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Consolidated Net Income stood at -$12.8 million in 2020, then surged by 32.99% to -$8.6 million in 2021, then tumbled by 212.94% to -$26.8 million in 2022, then tumbled by 72.00% to -$46.0 million in 2023, then slumped by 129.13% to -$105.5 million in 2024.